Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/27495
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMONNIER, Annelie-
dc.contributor.authorSchouten, J.-
dc.contributor.authorTebano, G.-
dc.contributor.authorZanichelli, V.-
dc.contributor.authorHuttner, B. D.-
dc.contributor.authorPulcini, C.-
dc.contributor.authorÅrdal, C.-
dc.contributor.authorHarbarth, S.-
dc.contributor.authorHulscher, M. E.-
dc.contributor.authorGYSSENS, Inge-
dc.date.accessioned2018-12-07T14:24:45Z-
dc.date.available2018-12-07T14:24:45Z-
dc.date.issued2019-
dc.identifier.citationClinical infectious diseases, 68 (11), p. 1952-1959-
dc.identifier.issn1058-4838-
dc.identifier.urihttp://hdl.handle.net/1942/27495-
dc.description.abstractAntibiotic resistance is a growing threat to global public health. The World Health Organization’s Global Action Plan on Antimicrobial Resistance recommends engaging multisectoral stakeholders to tackle the issue. However, so far, few studies have addressed barriers to antibiotic development, equitable availability, and responsible antibiotic use from the perspective of stakeholders outside healthcare facilities or patient communities: the so-called third-party stakeholders. Third-party stakeholders include, inter alia, governments, regulatory agencies, and professionals working in antibiotic research and development and medical ethics. This viewpoint provides an overview of barriers to antibiotic development, equitable availability of effective antibiotics, and the responsible use of antibiotics. The barriers were identified in an exploratory, qualitative interview study with an illustrative sample of 12 third-party stakeholders. Recommendations to lift these barriers are presented, together with examples of recently-made progress. The recommendations should guide future antibiotic policies and multisectoral policy action.-
dc.description.sponsorshipThis work was supported by the Innovative Medicines Initiative Joint Undertaking (grant number 115618 to The Driving Reinvestment in Research and Development and Responsible Antibiotic Use project); the European Union's Seventh Framework Programme (grant number FP7/2007-2013); and the European Federation of Pharmaceutical Industries and Associations (in-kind contribution).-
dc.language.isoen-
dc.rightsThe Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciy824-
dc.subject.othermultisectoral stakeholders-
dc.subject.otherbarriers and facilitators-
dc.subject.otherantimicrobial resistance-
dc.subject.otherantibiotic access-
dc.subject.otherantibiotic discovery-
dc.subject.otherglobal health-
dc.titleEnsuring antibiotic development, equitable availability and responsible use of effective antibiotics: recommendations for multisectoral action-
dc.typeJournal Contribution-
dc.identifier.epage1959-
dc.identifier.issue11-
dc.identifier.spage1952-
dc.identifier.volume68-
local.format.pages8-
local.bibliographicCitation.jcatA1-
dc.description.notesGyssens, IC (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Geert Grootepl 8, NL-6525 GA Nijmegen, Netherlands. inge.gyssens@radboudumc.nl-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1093/cid/ciy824-
dc.identifier.pmid30256927-
dc.identifier.isi000469504700025-
dc.identifier.eissn1537-6591-
local.provider.typePubMed-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorMONNIER, Annelie-
item.contributorSchouten, J.-
item.contributorTebano, G.-
item.contributorZanichelli, V.-
item.contributorHuttner, B. D.-
item.contributorPulcini, C.-
item.contributorÅrdal, C.-
item.contributorHarbarth, S.-
item.contributorHulscher, M. E.-
item.contributorGYSSENS, Inge-
item.fullcitationMONNIER, Annelie; Schouten, J.; Tebano, G.; Zanichelli, V.; Huttner, B. D.; Pulcini, C.; Årdal, C.; Harbarth, S.; Hulscher, M. E. & GYSSENS, Inge (2019) Ensuring antibiotic development, equitable availability and responsible use of effective antibiotics: recommendations for multisectoral action. In: Clinical infectious diseases, 68 (11), p. 1952-1959.-
item.accessRightsOpen Access-
item.validationecoom 2020-
crisitem.journal.issn1058-4838-
crisitem.journal.eissn1537-6591-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
ciy824.pdfPublished version182.94 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.